Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Pandemic-response adenoviral vector and RNA vaccine manufacturing

View ORCID ProfileZoltán Kis, Kyungjae Tak, Dauda Ibrahim, Maria M Papathanasiou, Benoît Chachuat, Nilay Shah, Cleo Kontoravdi
doi: https://doi.org/10.1101/2021.08.20.21262370
Zoltán Kis
1The Sargent Centre for Process Systems Engineering, Department of Chemical Engineering, Imperial College London, UK
2Department of Chemical and Biological Engineering, The University of Sheffield
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Zoltán Kis
  • For correspondence: z.kis10@imperial.ac.uk cleo.kontoravdi98@imperial.ac.uk
Kyungjae Tak
1The Sargent Centre for Process Systems Engineering, Department of Chemical Engineering, Imperial College London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dauda Ibrahim
1The Sargent Centre for Process Systems Engineering, Department of Chemical Engineering, Imperial College London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria M Papathanasiou
1The Sargent Centre for Process Systems Engineering, Department of Chemical Engineering, Imperial College London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benoît Chachuat
1The Sargent Centre for Process Systems Engineering, Department of Chemical Engineering, Imperial College London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nilay Shah
1The Sargent Centre for Process Systems Engineering, Department of Chemical Engineering, Imperial College London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cleo Kontoravdi
1The Sargent Centre for Process Systems Engineering, Department of Chemical Engineering, Imperial College London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: z.kis10@imperial.ac.uk cleo.kontoravdi98@imperial.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Rapid global COVID-19 pandemic response by mass vaccination is currently limited by the rate of vaccine manufacturing. This study presents a techno-economic feasibility assessment and comparison of three vaccine production platform technologies deployed during the COVID-19 pandemic: (1) adenovirus-vectored (AVV) vaccines, (2) messenger RNA (mRNA) vaccines, and (3) the newer self-amplifying RNA (saRNA) vaccines. Besides assessing the baseline performance of the production process, the impact of key design and operational uncertainties on the productivity and cost performance of these vaccine platforms were also evaluated using variance-based global sensitivity analysis. Cost and resource requirement projections were also computed for manufacturing multi-billion vaccine doses for covering the current global demand shortage and for providing annual booster immunizations. This model-based assessment provides key insights to policymakers and vaccine manufacturers for risk analysis, asset utilisation, directions for future technology improvements and future epidemic/pandemic preparedness, given the disease-agnostic nature of these vaccine production platforms.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This research is partly funded by UK Research and Innovation (UKRI) via the Engineering and Physical Sciences Research Council (EPSRC) grant on COVID-19/SARS-CoV-2 vaccine manufacturing and supply-chain optimisation (EP/V01479X/1) and the Future Vaccine Manufacturing Research Hub at UCL-Oxford (EP/R013756/1). Additional financial support from the Department of Health and Social Care using UK Aid funding as managed by the EPSRC (EP/R013764/1) is also gratefully acknowledged. The views expressed in this publication are those of the author(s) and not necessarily those of the Department of Health and Social Care. The authors gratefully acknowledge insightful discussions with Robin Shattock (Imperial College London, UK), Sandy Douglas (The Jenner Institute, UK), Harvey Branton (Centre for Process Innovation, UK) and John Liddell (Centre for Process Innovation, UK).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

No ethical approval was required for this computational modelling study.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data is available from: https://github.com/ZKis-ZK/RNA_AVV_vaccine_production-cost_modelling_global_sensitivity_analysis

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted September 02, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Pandemic-response adenoviral vector and RNA vaccine manufacturing
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Pandemic-response adenoviral vector and RNA vaccine manufacturing
Zoltán Kis, Kyungjae Tak, Dauda Ibrahim, Maria M Papathanasiou, Benoît Chachuat, Nilay Shah, Cleo Kontoravdi
medRxiv 2021.08.20.21262370; doi: https://doi.org/10.1101/2021.08.20.21262370
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Pandemic-response adenoviral vector and RNA vaccine manufacturing
Zoltán Kis, Kyungjae Tak, Dauda Ibrahim, Maria M Papathanasiou, Benoît Chachuat, Nilay Shah, Cleo Kontoravdi
medRxiv 2021.08.20.21262370; doi: https://doi.org/10.1101/2021.08.20.21262370

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (271)
  • Allergy and Immunology (557)
  • Anesthesia (135)
  • Cardiovascular Medicine (1769)
  • Dentistry and Oral Medicine (238)
  • Dermatology (173)
  • Emergency Medicine (316)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (662)
  • Epidemiology (10812)
  • Forensic Medicine (8)
  • Gastroenterology (594)
  • Genetic and Genomic Medicine (2960)
  • Geriatric Medicine (288)
  • Health Economics (534)
  • Health Informatics (1933)
  • Health Policy (836)
  • Health Systems and Quality Improvement (745)
  • Hematology (293)
  • HIV/AIDS (633)
  • Infectious Diseases (except HIV/AIDS) (12525)
  • Intensive Care and Critical Care Medicine (696)
  • Medical Education (300)
  • Medical Ethics (87)
  • Nephrology (324)
  • Neurology (2808)
  • Nursing (152)
  • Nutrition (433)
  • Obstetrics and Gynecology (559)
  • Occupational and Environmental Health (597)
  • Oncology (1473)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (257)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (381)
  • Pediatrics (868)
  • Pharmacology and Therapeutics (367)
  • Primary Care Research (338)
  • Psychiatry and Clinical Psychology (2646)
  • Public and Global Health (5383)
  • Radiology and Imaging (1016)
  • Rehabilitation Medicine and Physical Therapy (597)
  • Respiratory Medicine (727)
  • Rheumatology (330)
  • Sexual and Reproductive Health (290)
  • Sports Medicine (279)
  • Surgery (327)
  • Toxicology (48)
  • Transplantation (150)
  • Urology (126)